AI assistant
NNIT — Earnings Release 2018
May 15, 2018
3409_iss_2018-05-15_de254282-b143-48af-9c45-aab6115721aa.pdf
Earnings Release
Open in viewerOpens in your device viewer
Company announcement 7/2018 Søborg/Copenhagen, May 15, 2018
Financial report for Q1 2018
NNIT delivers an operating profit margin of 8.7% while revenue declines by 2.3% despite a revenue increase of 12% from non-Novo Nordisk customers
Performance highlights for Q1 2018
- Revenue from non-Novo Nordisk customers increased by 12% supported by strong growth from both enterprise and international life sciences customers of more than 20%. However, due to decline in revenue from the Novo Nordisk Group of 20% and the timing of Easter total revenue declined by 2.3% in reported currencies
- Adjusted for the timing of Easter revenue development was almost flat
- The share of revenue from non-Novo Nordisk customers increased from 55 % in Q1 2017 to 63% in Q1 2018
- Operating profit margin was 8.7% in reported currencies compared to 10.5% in 2017
- Adjusting for the timing of Easter the operating profit margin was 10.5%
- Net profit of DKK 46m in Q1 2018 was a decrease of 18% compared to Q1 2017. Adjusted for the timing of Easter net profit increased by 1.4% compared to last year
- Free cash flow for Q1 2018 was DKK 143m compared to DKK 163m in Q1 2017
- Order backlog for 2018 at the beginning of Q2 2018 was DKK 2,487m, an increase of 2.8% compared to the same time last year. The backlog for the following two years increased by 20%
- Outlook for 2018 is:
- Revenue growth of 3-6% in constant currencies (previously 4-7%)
- Expected operating profit margin of 10-10.5% in constant currencies
- The expected level of investments in 2018 is 6-8% of total revenue
- Based on the strong cash flow NNIT will pay out an interim dividend in August 2018 of DKK 49.1m in cash equal to DKK 2 per share of a nominal value of DKK 10
Per Kogut, CEO at NNIT says about the results for the first three months of 2018: "I am encouraged by the continued strong growth in particular the enterprise and international life sciences customer groups. The decline in revenue from the Novo Nordisk Group was larger than expected and we have therefore adjusted our revenue growth guidance for 2018 to 3-6%. Under these circumstances, I am pleased that we have maintained our operating profit margin guidance of 10-10.5%."
Financial Overview
| DKK million | Q1 2018 (reported) |
Q1 2018 (constant)* |
Q1 2017* | Pct./pp Change (reported) |
Pct./pp Change (constant) |
|---|---|---|---|---|---|
| Revenue | 699 | 707 | 715 | -2.3% | -1.2% |
| Gross margin | 17.1% | 16.7% | 18.9% | -1.8pp | -2.2pp |
| Operating profit | 6 1 |
5 9 |
7 5 |
-19.0% | -21.4% |
| Operating profit margin | 8.7% | 8.3% | 10.5% | -1.8pp | -2.1pp |
| Net profit | 4 6 |
n.a. | 5 6 |
-18.2% | n.a. |
| Investments | 5 3 |
n.a. | 6 7 |
-21.1% | n.a. |
| Free cash flow | 143 | n.a. | 163 | -12.3% | n.a. |
*Constant currencies measured using average exchange rates for Q1 2017
NNIT has implemented IFRS15 and IFRS 16 which impacts both reported and comparison figures. All figures, both 2018 and 2017, have been restated to IFRS 15 and IFRS 16. Please see note 1 for further details.
Guidance 2018
The order backlog for 2018 at the beginning of Q2 2018 increased by DKK 68.3m, or by 2.8%, to DKK 2,457m compared to the order backlog for 2017 at the beginning of Q2 2017.
The guidance for 2018 revenue growth is 3-6% in constant currencies. The growth is based on IFRS 15 restated 2017 revenue of DKK 2,851m. However, uncertainty regarding our guidance is increasing due to continued decline in sales to the Novo Nordisk Group.
The operating profit margin in constant currencies is expected to be in the interval 10- 10.5%.
| Guidance for 2018 | Guidance at Q4 2017 | Long-term targets | |
|---|---|---|---|
| Revenue growth In constant currencies as reported* |
3-6% Around 0.3pp lower |
4-7% Around 0.4pp lower |
> 5% |
| Operating profit margin In constant currencies as reported* |
10-10.5% Around 0.2pp higher |
10-10.5% Around 0.4pp higher |
- > 10% |
| Investments / Revenue*** | 6-8% | 6-8% |
*Constant currencies measured using average exchange rates for 2017
**Based on exchange rates as of May 9, 2018 as illustrated under key currency assumptions on page 21 *** Investments and data center investments are in 2018 expected to be between 6-8 percent of total revenue. Around 1pp
relates to the data center. The total data center investment is expected to be around DKK 250m in the period 2016 to 2018.
The expectations are based on a number of important assumptions, including that relevant macroeconomic trends will not significantly change business conditions for NNIT during 2018, that business performance, customer and competitor actions will remain stable and that key currency exchange rates will remain at the current levels versus Danish kroner (as of May 9, 2018).
About NNIT
NNIT A/S is one of Denmark's leading IT service providers and consultancies. NNIT A/S offers a wide range of IT services and solutions to its customers, primarily in the life sciences sector in Denmark and internationally and to customers in the public, enterprise and finance sectors in Denmark. As of March 31, 2018 NNIT A/S had 3,101 employees. NNIT has approximately 350 clients of which around 100 are located outside Denmark. Some 20% are international life science clients (January 2018). For more information please visit www.nnit.com.
Conference call details
NNIT will host a teleconference May 16, 2018 at 10:30 CET about the financial report for Q1 2018. Please visit the NNIT webpage at www.nnit.com to access the teleconference, which can be found under 'Investors – Events & presentations'. Presentation material will be available on the website approximately one hour prior to the start of the presentation.
Conference call details https://nnit.eventcdn.net/20180516
Participant telephone numbers: Denmark: +45 3544 5583 United Kingdom: +44 20 3194 0544 Sweden: +46 8 5664 2661 United States: +1 855 269 2604
Financial Calendar 2018
| August 17, 2018 | Interim report for the first six months of 2018 |
|---|---|
| August 22, 2018 | Interim dividend ex dividend date |
| August 23, 2018 | Interim dividend record date |
| August 24, 2018 | Interim dividend payment date |
| October 25, 2018 | Interim report for the first nine months of 2018 |
Forward-looking statements
This announcement contains forward-looking statements. Words such as 'believe', 'expect', 'may', 'will', 'plan', 'strategy', 'prospect', 'foresee', 'estimate', 'project', 'anticipate', 'can', 'intend', 'outlook', 'guidance', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Statements regarding the future are subject to risks and uncertainties that may result in considerable deviations from the outlook set forth. Furthermore, some of these expectations are based on assumptions regarding future events which may prove incorrect.
Please also refer to the overview of risk factors in the 'risk management' section on page 29-32 in the Annual Report 2017.
Contacts for further information
Investor relations: Media relations: Klaus Hosbond Skovrup Helga Heyn Head of Investor Relations NNIT Communications Tel: +45 3079 5355 Tel: +45 3077 8141 [email protected] [email protected]
Financial figures and highlights
| DKK million, reported currencies | Q1 2018 | Q1 20171 | Change Q1 |
Total 20171 |
|---|---|---|---|---|
| Financial performance | ||||
| Revenue | ||||
| Novo Nordisk Group | 256.1 | 320.9 | -20.2% | 1,185.4 |
| Other Life Sciences | 99.2 | 88.6 | 12.0% | 374.6 |
| Enterprise | 187.3 | 151.0 | 24.0% | 684.3 |
| Public | 99.4 | 86.1 | 15.4% | 353.9 |
| Finance | 56.6 | 68.4 | -17.3% | 253.2 |
| Revenue by customer group | 698.5 | 715.1 | -2.3% | 2,851.4 |
| IT Operation Services | 425.6 | 472.7 | -10.0% | 1,831.9 |
| IT Solution Services Revenue by business area |
272.9 698.5 |
242.4 715.1 |
12.6% -2.3% |
1,019.5 2,851.4 |
| EBITDA | 122.5 | 133.1 | -8.0% | 495.5 |
| Depreciations and amortizations | 61.8 | 58.1 | 6.3% | 231.9 |
| Operating profit (EBIT) | 60.7 | 75.0 | -19.0% | 263.6 |
| Net financials | -2.0 | -3.7 | -45.8% | -10.0 |
| Net profit | 45.8 | 56.0 | -18.2% | 199.5 |
| Investments in tangible assets | 28.4 | 65.7 | -56.8% | 326.6 |
| Investments in intangible assets and acquisition in subsidiaries | 1.1 | 1.6 | -31.4% | 108.3 |
| Total assets | 2,121.5 | 2,084.4 | 1.8% | 2,319.7 |
| Equity | 928.6 | 846.2 | 9.7% | 974.0 |
| Dividends paid2 | 56.4 | 53.4 | 5.8% | 102.0 |
| Free cash flow | 142.9 | 162.9 | -12.3% | -4.4 |
| Earnings per share | ||||
| Earnings per share (DKK) | 1.87 | 2.31 | -18.5% | 8.20 |
| Diluted earnings per share (DKK) | 1.86 | 2.30 | -19.7% | 8.00 |
| Employees | ||||
| Average number of full-time employees | 3,047 | 2,865 | 6.4% | 2,937 |
| Financial ratios | ||||
| Gross profit margin | 17.1% | 18.9% | -1.8pp | 18.1% |
| EBITDA margin | 17.5% | 18.6% | -1.1pp | 17.4% |
| Effective tax rate | 21.9% | 21.4% | 0.5pp | 21.3% |
| Investments/Revenue | 4.2% | 9.4% | -5pp | 15.3% |
| Return on equity3 | 21.3% | 28.5% | -34.5pp | 21.9% |
| Solvency ratio | 43.8% | 40.6% | 3.2pp | 42.0% |
| Return on invested capital (ROIC)3,4 Cash to earnings3 |
26.4% -2.6% |
43.1% 99.8% |
-16.7pp -102.4pp |
25.7% -2.2% |
| Cash to earnings (three-year average)3 | 84.9% | 111.5% | -26.6pp | 62.9% |
| Long-term financial metrics | ||||
| Revenue growth Operating profit margin |
-2.3% 8.7% |
7.9% 10.5% |
-10.2pp -1.8pp |
3.1% 9.2% |
| Additional numbers5 Order entry backlog for the current year |
2,487.1 | 2,418.8 | 2.8% | - |
| Order entry backlog for the following years 2+36 | 2,564.0 | 2,129.1 | 20.4% | - |
1) Numbers includes the effect of the implementation of IFRS 15 and IFRS 16 (please see note 1 for further information)
2) Dividends paid in 2017 included ordinary dividend regarding 2016 and interim dividend for 2017.
3) Financial metrics are moving annual total (MAT), i.e. annualized. Cash to earnings (three-year-average) is calculated using the past 36 months
4) Net profit/Average invested capital.
5) Order entry backlog figures in the 2017 column have been restated to reflect the implementation of IFRS15. Please see note 9 for further information. Backlog represents anticipated revenue from contracts or orders executed but not yet completed or performed in full, and the revenue that is expected to be recognized in the future.
6) Year 2+3 represents 2019 and 2020 in the 2018 column and 2018 and 2019 in the 2017 column etc.
4 of 22 NNIT A/S Østmarken 3A Telephone: +45 7024 4242 2860 Søborg www.nnit.com Denmark CVR No: 21 09 31 06
Highlights
Below are the key highlights for Q1 2018 and the order backlog for 2018 at the beginning of Q2 2018.
Sales
The order backlog for 2018 at the beginning of Q2 2018 increased by DKK 68.3m, or by 2.8%, to DKK 2,487m compared to the order backlog for 2017 at the beginning of Q2 2017. At the beginning of Q2 2018 the order backlog for 2019 and 2020 was 20% higher than the order backlog for 2018 and 2019 at the beginning of Q2 2017. See outlook and backlog section for further information.
Key wins in Q1 2018:
- New IT-infrastructure operations and application maintenance outsourcing contract with STARK Danmark A/S representing a lower medium-size three-digit DKK million amount over a four-year period, see press release February 22, 2018
- New infrastructure outsourcing contract with an existing enterprise customer representing a mid-size double-digit DKK million amount over a five-year period
- Extension of infrastructure outsourcing contract with an existing public customer representing a minor double-digit DKK million amount over a two-year period
- New SAP implementation and operation contract with a Chinese customer representing a minor double-digit DKK million amount over a four-year period
- First SAP EUGDPR implementation project won with a high single-digit DKK million amount
Key wins after Q1 2018:
New IT-infrastructure operations contract with NNE representing a high doubledigit DKK million amount over a five-year period, see press release April 26, 2018
Distribution of interim dividend
Based on the strong cash flow NNIT expects to pay out an interim dividend for the calendar year 2018 in August 2018 of DKK 49.1m in cash equal to DKK 2 per share of a nominal value of DKK 10 as seen in August 2017.
Performance overview
| DKK million (reported currencies) |
Q1 2018 | Q1 2017 | Change |
|---|---|---|---|
| Revenue | 698.5 | 715.1 | -2.3% |
| Cost of goods sold | 579.1 | 579.7 | -0.1% |
| Gross profit | 119.4 | 135.4 | -11.9% |
| Gross profit margin | 17.1% | 18.9% | -1.8pp |
| Sales and marketing costs | 32.0 | 32.8 | -2.6% |
| Administrative expenses | 26.7 | 27.6 | -3.5% |
| Operating profit | 60.7 | 75.0 | -19.0% |
| Operating profit margin | 8.7% | 10.5% | -1.8pp |
| Net financials | -2.0 | -3.7 | -45.8% |
| Profit before tax | 58.7 | 71.2 | -17.6% |
| Tax | 12.9 | 15.2 | -15.6% |
| Effec tive tax rate |
21.9% | 21.4% | 0.5pp |
| Net profit | 45.8 | 56.0 | -18.2% |
Revenue in reported currencies decreased by 2.3% in Q1 2018 (1.2% in constant currencies) due to a 20% decline in revenue from the Novo Nordisk Group following very low project activity in Q1 2018 and a high comparison base in Q1 2017 which was impacted by infrastructure projects with a high degree of hardware. Further, the timing of Easter impacted revenue growth negatively with approximately 2.0pp. Revenue from non-Novo Nordisk customers increased by 12% driven by the enterprise, international life sciences and public customer groups. SCALES had a positive impact on total revenue of 5.7pp in Q1 2018.
For a detailed performance overview in both reported and constant currencies please see note 6 on page 21. Comparisons in this financial report are hereafter in reported currencies. NNIT's major currencies have depreciated giving operating profit margin in 2018 a tailwind of 0.4pp whereas revenue growth was impacted negatively by 1.1pp.
Cost of goods sold decreased by 0.1% in Q1 2018 compared to the same period last year. The gross profit margin was 17.1% in Q1 2018 compared to 18.9% in Q1 2017. The decrease in gross profit margin for Q1 2018 was driven by the decline in revenue from the Novo Nordisk Group and the timing of Easter which was partly countered by revenue outside the Novo Nordisk Group. The cost including depreciations from the newly established data center also impacts the gross profit margin negatively due to low utilization as expected under start-up. Adjusting for the timing of Easter, the gross profit margin was 18.7% in Q1 2018.
Sales and marketing costs decreased by 2.6% in Q1 2018 mainly due to timing of expenses.
Administrative expenses decreased by 3.5% in Q1 2018 compared to Q1 2017 mainly due to savings from the layoffs in staff functions in Q4 2017.
Operating profit in Q1 2018 decreased by 19% to DKK 60.7m corresponding to an operating profit margin of 8.7% (8.3% in constant currencies) compared to 10.5% in Q1 2017. The decrease was due to the decline in Novo Nordisk revenue and the timing of Easter. Adjusted for the timing of Easter, the operating profit margin was 10.5% in Q1 2018.
Net financials in Q1 2018 were negative DKK 2.0m which is an improvement of DKK 1.7m compared to Q1 2017. The improvement was mainly due to a gain on cash flow hedges of DKK 0.8m in Q1 2018 compared to a loss of DKK 0.2m in Q1 2017 equivalent to a net improvement of DKK 1.0m. Furthermore, the improvement was impacted by a
2860 Søborg www.nnit.com
negative value adjustment of DKK 0.6 in Q1 2017 of Novo Nordisk shares (covering the long-term incentive program from previous years).
The effective tax rate in Q1 2018 was 21.9% representing an increase of 0.5pp compared to Q1 2017. The increase is due to a reduction in permanent adjustments as NNIT A/S no longer holds Novo Nordisk shares as well as a higher tax in subsidiaries mainly due to SCALES.
Net profit in Q1 2018 was DKK 45.8m corresponding to a decrease of 18% compared to Q1 2017. The decrease in Q1 2018 was impacted by the lower revenue from the Novo Nordisk Group and the timing of the Easter. Adjusting for the timing of Easter, net profit increased by 1.4% in Q1 2018 compared to same period last year.
Revenue
Revenue distribution:
| DKKm (reported currencies) |
Q1 2018 | Q1 2017 | Pct Change (reported) |
|---|---|---|---|
| Novo Nordisk Group | 256.1 | 320.9 | -20.2% |
| Other Life Sciences | 99.2 | 88.6 | 12.0% |
| Enterprise | 187.3 | 151.0 | 24.0% |
| Public | 99.4 | 86.1 | 15.4% |
| Finance | 56.6 | 68.4 | -17.3% |
| Total | 698.5 | 715.1 | -2.3% |
Revenue declined 2.3% in Q1 2018 primarily driven by a decline in revenue from the Novo Nordisk Group of 20%. The enterprise, public and other life sciences customer groups increased by 24%, 15% and 12%, respectively, while the finance customer group declined by 17%.
As a consequence of the decline in revenue from the Novo Nordisk Group, the share of NNIT's revenue from customers outside the Novo Nordisk Group increased to 63% in Q1 2018 compared to 55% in Q1 2017.
Novo Nordisk:
NNIT's revenue from the Novo Nordisk Group revenue decreased by DKK 64.8m in Q1 2018 corresponding to a decrease of 20% mainly due lower project activity, a high comparison base in Q1 2017 which was impacted by infrastructure projects with a high degree of hardware and also the timing of Easter. Adjusted for hardware revenue and the timing of Easter, the growth from the Novo Nordisk Group would have been negative with approximately 10% in Q1 2018.
Other life sciences:
Revenue from other life sciences customers increased 12% or DKK 10.6m in Q1 2018 driven by strong growth from international life science customers of more than 20% continuing the development from recent quarters.
Enterprise:
Revenue in Q1 2018 increased by DKK 36.3m corresponding to an increase of 24% in Q1 2018 compared to the same period last year. Revenue growth was driven by SCALES' customers, PANDORA and STARK. The impact on financials from STARK started in March 2018.
Public:
Revenue in Q1 2018 increased by DKK 13.3m corresponding to 15% compared to the same period last year. The increase was mainly due to a settlement with a customer within IT Operation Services in Q1 2017 as well as a positive contribution from
2860 Søborg www.nnit.com
SCALES' customers in this segment.
Finance:
Revenue in Q1 2018 decreased by DKK 11.8m or 17% due to a customer contract within IT Operation Services which was not extended when it expired in June 2017 partly offset by expansion of existing customers.
Order backlog
Backlog for the following two calendar years, beginning of quarter
The order backlog for 2018 at the beginning of Q2 2018 increased by DKK 68.3m, or by 2.8%, to DKK 2,487m compared to the order backlog for 2017 at the beginning of Q2 2017. It should be noted that the revenue reversal of DKK 26m in Q3/Q4 2017 regarding a customer in the public customer group had a negative impact on full year revenue for 2017, but was not reflected in the backlog at the beginning of Q2 2017.
8 of 22 NNIT A/S Østmarken 3A Telephone: +45 7024 4242 2860 Søborg www.nnit.com Denmark CVR No: 21 09 31 06
Order backlog from the Novo Nordisk Group declined with 9.4%, while other customers increased 12.0%. The increase from other customers is mainly driven by SCALES' customers, PANDORA, STARK and international life sciences customers. The decrease in the order backlog from the Novo Nordisk Group is explained by lower project activity in the Novo Nordisk Group.
At the beginning of Q2 2018 the order backlog for 2019 and 2020 was 20% higher than the order backlog for 2018 and 2019 at the beginning of Q2 2017. The Novo Nordisk Group backlog increased 41% while other customekrs increased 8.3%. The increase in the order entry backlog is due to extension of the corporate core IT infrastructure outsourcing contract with Novo Nordisk, the five year contract extension with Arla and the new contract with STARK partly countered by the expiry of several large infrastructure agreements in 2019 and 2020 in other customer groups.
Employees, end-of-period
At the end of Q1 2018, the number of employees increased by 234 FTE corresponding to 8.1% compared to the same period last year. The increase was primarily due to the inclusion of around 50 employees taken over from STARK, 103 SCALES FTEs in Denmark and 20 FTEs in Norway respectively. Excluding SCALES and the employees from STARK the underlying growth was only 2.1% entirely driven by countries outside Denmark whereas FTEs in Denmark decreased by 113. The increase outside Denmark was in-line with the long-term offshoring strategy, increasing primarily in the Philippines (74 FTEs), China (71 FTEs) and Czech Republic (25 FTEs). Denmark increased by 40 FTEs entirely due to SCALES and the employees from STARK, while Switzerland, Germany, United Kingdom, United States and Norway combined grew by 24 FTEs also due to SCALES and increased activity within international life sciences.
Balance sheet
Total assets at March 31, 2018 increased by DKK 37.1m to DKK 2,121.5m compared to DKK 2,084.4m at March 31, 2017 primarily due to an increase in intangible assets in connection with the acquisition of SCALES (DKK 187.2m) and tangible assets due to the new data center partly countered by a decrease in cash and cash equivalents.
The net of Cash and cash equivalents amounted to DKK 7.2m at March 31, 2018, a decrease of DKK 255.5m compared to March 31, 2017. The decrease was due to the acquisition of SCALES (DKK 98.0m), increased investments in a new data center (DKK 161.7m), acquisition of treasury shares (DKK 37.3m) and the payment of interim dividend for 2017 (DKK 48.7m) and ordinary dividend for 2017 (DKK 56.4m) partly countered by net profits from operating activities.
2860 Søborg www.nnit.com
9 of 22 NNIT A/S Østmarken 3A Telephone: +45 7024 4242 Denmark CVR No: 21 09 31 06
Equity at March 31, 2018 amounted to DKK 928.6m, an increase of DKK 82.4m compared to March 31, 2017. The improvement was mainly due to net profits for the period offset by paid interim dividends for 2017 (DKK 48.7m) and ordinary dividends for 2017 (DKK 56.4m).
Investments
Investments amounted to DKK 29.5m (hereof DKK 15.3m related to the new data center) in Q1 2018 compared to DKK 67.3m (hereof DKK 34.7m related to the new data center) in Q1 2017. The decrease in investments is mainly related to timing of hardware purchases in connection with outsourcing contracts.
Free cash flow
The free cash flow for Q1 2018 was DKK 142.9m which was DKK 20.0m below Q1 2017 due to the development in working capital. In Q1 2017 trade receivables decreased significantly compared to Q4 2016 due to payment of project milestones and hardware contracts being invoiced in Q4 2016 and paid in Q1 2017. A similar development was seen to a smaller extent in Q1 2018. Based on the strong cash flow NNIT expects to pay out an interim dividend in August 2018 as in August 2017.
Business areas
| IT Operation Services | ||||||||
|---|---|---|---|---|---|---|---|---|
| DKK million (reported currencies) |
Q1 2018 | Q1 2017 | Change |
|---|---|---|---|
| Revenue | |||
| Novo Nordisk Group | 169.9 | 225.0 | -24.5% |
| Non-Novo Nordisk Group | 255.7 | 247.7 | 3.2% |
| Total | 425.6 | 472.7 | -10.0% |
| Costs | 393.3 | 421.8 | -6.8% |
| Operating profit | 32.3 | 50.9 | -36.5% |
| Operating profit margin | 7.6% | 10.8% | -3.2pp |
IT Operation Services revenue decreased by 10% in Q1 2018 following a 25% decline in revenue from the Novo Nordisk Group mainly due to lower project activity, price reductions in major service level agreements, a high comparison base in Q1 2017 which was impacted by infrastructure projects with a high degree of hardware and the timing of Easter,. Revenue from non-Novo Nordisk Group increased by 3.2% driven by STARK and a settlement with a customer within the public customer group in Q1 2017 partly
2860 Søborg www.nnit.com
10 of 22 NNIT A/S Østmarken 3A Telephone: +45 7024 4242 Denmark CVR No: 21 09 31 06
countered by a customer within the finance customer group which was not extended when it expired in June 2017.
Operating profit decreased by 37% in Q1 2018 compared to Q1 2017 mainly due to the declining revenue from the Novo Nordisk Group and the customer within the finance customer group which was not extended as well as the timing of Easter. The cost including depreciations from the newly established data center also impacts the operating profit margin negatively due to low utilization. Operating profit margin in Q1 2018 was 7.6% compared to 10.8% in Q1 2017 due to the mentioned reasons. Adjusted for Easter the operating profit margin in Q1 was 8.5%.
IT Solution Services
| DKK million (reported currencies) |
Q1 2018 | Q1 2017 | Change |
|---|---|---|---|
| Revenue | |||
| Novo Nordisk Group | 86.2 | 95.9 | -10.1% |
| Non-Novo Nordisk Group | 186.7 | 146.5 | 27.5% |
| Total | 272.9 | 242.4 | 12.6% |
| Costs | 244.5 | 218.3 | 12.0% |
| Operating profit | 28.4 | 24.1 | 17.8% |
| Operating profit margin | 10.4% | 9.9% | 0.5pp |
IT Solution Services revenue increased by 13% in Q1 2018 driven by non-Novo Nordisk Group customers, whereas revenue from the Novo Nordisk Group decreased by 10% due to a decline in project activities and the timing of Easter. The increase in non-Novo Nordisk Group revenue was due to SCALES' customers, PANDORA and STARK partly countered by the timing of Easter.
Operating profit in Q1 2017 increased by 18% following the increase in revenue and a higher average hourly rate on projects. Operating profit margin in Q1 2018 was 10.4% compared to 9.9% in Q1 2017, an increase of 0.5pp due to the above mentioned reasons.
Events after balance sheet date
There have been no events after the balance sheet date which would have a significant impact on an assessment of NNIT's financial position at March 31, 2018.
Management statement
Statement by the Board of Directors and the Executive Management on the unaudited interim consolidated financial statements of NNIT A/S as at and for the three months ended March 31, 2018
The Board of Directors and Executive Management ("Management") have reviewed and approved the interim consolidated financial statements of NNIT A/S (NNIT A/S, together with its subsidiaries, the "Group") for the first three months of 2018 with comparative figures for the first three months of 2017. The interim consolidated financial statements have not been audited or reviewed by the company's independent auditors.
The interim consolidated financial statements for the first three months of 2018 have been prepared in accordance with IAS 34 'Interim Financial Reporting', as adopted by the European Union and accounting policies set out in the annual report for 2017 of NNIT A/S. Furthermore, the interim consolidated financial statement for the first three months of 2018 and Management's review are prepared in accordance with additional Danish disclosure requirements for interim reports of listed companies.
In our opinion, the accounting policies used are appropriate and the overall presentation of the interim consolidated financial statements for the first three months of 2018 are adequate and give a true and fair view of the Group's assets, liabilities and financial position as at March 31, 2018 and of the results of the Group's operations and cash flow for the three months ended March 31, 2018. Furthermore, in our opinion, Management's review includes a true and fair account of the development in the operations and financial circumstances, of the results for the period and of the financial position of the Group as well as a description of the most significant risks and elements of uncertainty facing the Group in accordance with Danish disclosure requirements for listed companies.
Since the disclosure of the Group's most significant risks and uncertainties in the Annual Report for 2017 of NNIT A/S the risk of a larger decline in revenue from the Novo Nordisk Group has increased. Besides this no changes in the Group's most significant risks and uncertainties have occurred.
Søborg, May 15, 2018 Executive management
| Per Kogut CEO Board of Directors |
Carsten Krogsgaard Thomsen CFO |
|
|---|---|---|
| Carsten Dilling Chairman |
Peter H. J. Haahr Deputy Chairman |
Anne Broeng |
| Eivind Kolding | Christian Kanstrup | Caroline Serfass |
| Anders Vidstrup | Henrik Vienberg Andersen |
Consolidated financial statements
Income statement and Statement of comprehensive income
| Note | Q1 2018 | Q1 2017 1) | 12M 2017 1) | |
|---|---|---|---|---|
| DKK '000 | DKK '000 | DKK '000 | ||
| Income statement | 1 | |||
| Revenue | 2 | 698,502 | 715,112 | 2,851,387 |
| Cost of goods sold | 579,145 | 579,697 | 2,336,296 | |
| Gross profit | 119,357 | 135,415 | 515,091 | |
| Sales and marketing costs | 31,975 | 32,811 | 135,226 | |
| Administrative expenses | 26,681 | 27,649 | 116,301 | |
| Operating profit | 60,701 | 74,955 | 263,564 | |
| Financial income | 862 | 2,055 | 5,059 | |
| Financial expenses | 2,884 | 5,787 | 15,105 | |
| Profit before income taxes | 58,679 | 71,223 | 253,518 | |
| Income taxes | 12,869 | 15,242 | 53,993 | |
| Net profit for the period | 45,810 | 55,981 | 199,525 |
| Earnings per share | DKK | DKK | DKK |
|---|---|---|---|
| Earnings per share | 1.87 | 2.31 | 8.20 |
| Diluted earnings per share | 1.86 | 2.30 | 8.00 |
Statement of comprehensive income
| DKK '000 | DKK '000 | DKK '000 | |
|---|---|---|---|
| Net profit for the period | 45,810 | 55,981 | 199,525 |
| Other comprehensive income: | |||
| Items that will not be reclassified subsequently to the Income statement: | |||
| Remeasurement related to pension obligations | -15 | 0 | 4,798 |
| Tax on other comprehensive income | 7 | -454 | -1,314 |
| Items that will be reclassified subsequently to the Income statement, | |||
| when specific conditions are met: |
|||
| Currency revaluation related to subsidiaries (net) | -1,164 | 1,416 | -1,594 |
| Recycled to financial items | 804 | 165 | 2,799 |
| Unrealized value adjustments | 3,410 | 6,691 | 2,043 |
| Cash flow hedges | 4,214 | 6,856 | 4,842 |
| Tax on other comprehensive income related to cash flow hedges | -927 | -1,218 | -1,065 |
| Other comprehensive income, net of tax | 2,115 | 6,600 | 5,668 |
| Total comprehensive income | 47,925 | 62,581 | 205,193 |
| 1 ) The numbers includes the effect of the implementation of IFRS 15 and IFRS 16. Please refer to note 1 for a brigde between 2017 |
|||
previous practice and 2017 adjusted.
Balance sheet
Assets
| Note | March 31, 2018 | March 31, 20171) | Dec 31, 2017 1) | |
|---|---|---|---|---|
| DKK '000 | DKK '000 | DKK '000 | ||
| Intangible assets | 210,014 | 32,926 | 212,057 | |
| Tangible assets | 940,638 | 856,317 | 940,697 | |
| Contract assets | 173,643 | 160,701 | 179,330 | |
| Deferred tax | 57,761 | 52,010 | 65,017 | |
| Deposits | 32,766 | 28,975 | 32,637 | |
| Total non-current assets | 1,414,822 | 1,130,929 | 1,429,738 | |
| Inventories | 1,686 | 2,435 | 1,566 | |
| Trade receivables | 3 | 451,192 | 419,177 | 574,808 |
| Work in progress | 3 | 77,564 | 109,703 | 56,069 |
| Other receivables and pre-payments | 150,676 | 140,255 | 164,432 | |
| Tax receivable | 10,694 | 3,848 | 0 | |
| Shares | 0 | 9,988 | 13,950 | |
| Derivative financial instruments | 7,672 | 5,349 | 4,598 | |
| Cash and cash equivalents | 7,182 | 262,715 | 74,577 | |
| Total current assets | 706,666 | 953,470 | 890,000 | |
| Total assets | 2,121,488 | 2,084,399 | 2,319,738 |
Equity and liabilities
| March 31, 2018 March 31, 2017 1) | Dec 31, 2017 1) | |||
|---|---|---|---|---|
| DKK '000 | DKK '000 | DKK '000 | ||
| Share capital | 250,000 | 250,000 | 250,000 | |
| Treasury shares | -4,676 | -7,500 | -6,567 | |
| Retained earnings | 623,060 | 589,291 | 665,914 | |
| Other reserves | 11,153 | 14,385 | 8,654 | |
| Proposed dividends | 49,070 | 0 | 55,990 | |
| Total equity | 928,607 | 846,176 | 973,991 | |
| Leasing leability | 281,875 | 345,823 | 295,950 | |
| Employee benefit obligation | 15,684 | 19,075 | 15,397 | |
| Contingent consideration (earn out) | 54,345 | 0 | 54,345 | |
| Provisions | 24,489 | 23,575 | 24,722 | |
| Total non-current liabilities | 376,393 | 388,473 | 390,414 | |
| Prepayments received | 3 | 234,863 | 291,091 | 293,653 |
| Leasing liability | 80,611 | 75,531 | 80,920 | |
| Bank overdraft | 0 | 0 | 93,194 | |
| Trade payables | 166,402 | 138,728 | 58,948 | |
| Employee cost payable | 201,401 | 227,505 | 255,421 | |
| Tax payables | 4,633 | 0 | 18,096 | |
| Other current liabilities | 128,050 | 102,975 | 132,083 | |
| Derivative financial instruments | 366 | 387 | 1,164 | |
| Employee benefit obligation | 0 | 11,343 | 21,694 | |
| Provisions | 162 | 2,190 | 160 | |
| Total current liabilities | 816,488 | 849,750 | 955,333 | |
| Total equity and liabilities | 2,121,488 | 2,084,399 | 2,319,738 | |
| Contingent liabilities and legal proceedings | 4 | |||
| Currency hedging | 5 | |||
| 1 ) The numbers includes the effect of the implementation of IFRS 15 and IFRS 16. Please refer to note 1 for a brigde between 2017 previous |
Currency hedging 5 practice and 2017 adjusted.
Statement of cash flow
| Q1 2018 | Q1 2017 1) | 12 M 2017 1) | ||
|---|---|---|---|---|
| DKK '000 | DKK '000 | |||
| Net profit for the period | Note | 45,810 | 55,981 | 199,525 |
| Reversal of non-cash items | 79,618 | 68,588 | 328,308 | |
| Interest received | 58 | 73 | 171 | |
| Interest paid | -844 | -761 | -3,750 | |
| Income taxes paid | -34,416 | -43,2750 | -80,220 | |
| Cash flow before change in working capital | 90,226 | 80,6060 | 444,034 | |
| Changes in working capital | 82,230 | 149,6770 | -10,753 | |
| Cash flow from operating activities | 172,456 | 230,2830 | 433,281 | |
| Capitalization of intangible assets | -1,083 | -1,579 | -10,279 | |
| Purchase of tangible assets | -52,020 | -68,351 | -323,710 | |
| Change in trade payables related to investments | 23,606 | 2,623 | -2,887 | |
| Dividends received | 0 | 192 | 317 | |
| Sale/(purchase) of shares (net) | 89 | 0 | 0 | |
| Payment of deposits | -129 | -246 | -3,142 | |
| Acquisition of subsidiary | 0 | 0 | -97,991 | |
| Cash flow from investing activities | -29,537 | -67,3610 | -437,692 | |
| Dividends paid | -56,418 | -53,350 | -102,037 | |
| Purchase of treasury shares | -37,345 | 0 | 0 | |
| Repayments of lease liability | -23,357 | -20,769 | -86,081 | |
| Cash flow from financing activities | -117,120 | -74,1190 | -188,118 | |
| Net cash flow | 25,799 | 88,803 | -192,529 | |
| Cash and cash equivalents at the beginning of the period | -18,617 | 173,912 | 173,912 | |
| Cash and cash equivalents at the end of the period | ,7,182 | 262,7150 | -18,617 | |
| Additional information2 : |
||||
| Cash and cash equivalents at the end of the period | 7,182 | 262,715 | -18,617 | |
| Undrawn committed credit facilities | 400,000 | 400,0000 | 306,806 | |
| Financial resources at the end of the period | 407,182 | 662,7150 | 288,189 | |
| Cash flow from operating activities Cash flow from investing activities |
172,456 -29,537 |
230,283 -67,361 |
433,281 -437,692 |
|
| Free cash flow | 142,919 | 162,922 | -4,411 | |
| 1 ) The numbers includes the effect of the implementation of IFRS 15 and IFRS 16. |
2 Additional non-IFRS measures. 'Financial resources at the end of the period' is defined as the sum of cash and cash equivalents at the end of the period and undrawn committed credit facilities. Free cash flow is defined as 'cash flow from operating activities' less 'cash flow from investing activities'.
Statement of changes in equity
| DKK '000 | Other reserves | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Share | Treasury | Retained | Currency | Cash flow | Tax | Total other | Proposed | ||
| March 31, 2018 | capital | shares | earnings | revaluation | hedges | reserves | dividends | Total | |
| Balance at the beginning of the period | 250,000 | -6,567 | 665,914 | 5,190 | 3,521 | -57 | 8,654 | 55,990 | 973,991 |
| Net profit for the period | 0 | 0 | 45,810 | 0 | 0 | 0 | 0 | 0 | 45,810 |
| Other comprehensive income for the period | 0 | 0 | -15 | -1,164 | 4,214 | -920 | 2,130 | 0 | 2,115 |
| Total comprehensive income for the period | 0 | 45,795 | -1,164 | 4,214 | -920 | 2,130 | 0 | 47,925 | |
| Transactions with owners: | |||||||||
| Transfer of treasury shares | 0 | -2,030 | -35,315 | -37,345 | |||||
| Share-based payments | 0 | 3,921 | 441 | 0 | 0 | 0 | 0 | 0 | 4,362 |
| Deferred tax on share-based payments | 0 | 0 | -3,908 | 0 | 0 | 0 | 0 | 0 | -3,908 |
| Adjustment to proposed dividend | -428 | 428 | 0 | ||||||
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -56,418 | -56,418 |
| Proposed interim dividend for 2018 | 0 | 0 | -49,070 | 0 | 0 | 0 | 0 | 49,070 | 0 |
| Total dividends for 2017 | 0 | 0 | -49,070 | 0 | 0 | 0 | 0 | 49,070 | 0 |
| Balance at the end of the period | 250,000 | -4,676 | 623,429 | 4,026 | 7,735 | -977 | 10,784 | 49,070 | 928,607 |
| DKK '000 | Other reserves | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Share | Treasury | Retained | Currency | Cash flow | Total other | Proposed | |||
| December 31, 2017 | capital | shares | earnings | revaluation | hedges | Tax | reserves | dividends | Total |
| Balance at the beginning of the period | 250,000 | -7,500 | 542,833 | 6,784 | -1,321 | 2,322 | 7,785 | 53,350 | 846,468 |
| Effect of IFRS 15 and IFRS 16 | -21,509 | -21,509 | |||||||
| Tax effect of IFRS 15 and 16 | 6,979 | 6,979 | |||||||
| Adjusted balance at the beginning of the period | 528,303 | 831,938 | |||||||
| Net profit for the period | 0 | 0 | 199,525 | 0 | 0 | 0 | 0 | 0 | 199,525 |
| Other comprehensive income for the period | 0 | 0 | 4,798 | -1,594 | 4,842 | -2,379 | 869 | 0 | 5,667 |
| Total comprehensive income for the period | 0 | 204,323 | -1,594 | 4,842 | -2,379 | 869 | 0 | 205,192 | |
| Transactions with owners: | |||||||||
| Transfer of treasury shares | 0 | 933 | 18,190 | 19,123 | |||||
| Share-based payments | 0 | 0 | 21,342 | 0 | 0 | 0 | 0 | 0 | 21,342 |
| Deferred tax on share-based payments | 0 | 0 | -1,567 | 0 | 0 | 0 | 0 | 0 | -1,567 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -102,037 -102,037 | |
| Interim dividend for 2017 | 0 | 0 | -48,687 | 0 | 0 | 0 | 0 | 48,687 | 0 |
| Proposed dividend for 2017 | 0 | 0 | -55,990 | 0 | 0 | 0 | 0 | 55,990 | 0 |
| Total dividends for 2017 | 0 | 0 | -104,677 | 0 | 0 | 0 | 0 | 104,677 | 0 |
| Balance at the end of the period | 250,000 | -6,567 | 665,914 | 5,190 | 3,521 | -57 | 8,654 | 55,990 | 973,991 |
| DKK '000 | Other reserves | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Share | Treasury | Retained | Currency | Cash flow | Tax | Total other | Proposed | ||
| March 31, 2017 | capital | shares | earnings | revaluation | hedges | reserves | dividends | Total | |
| Balance at the beginning of the period | 250,000 | -7,500 | 542,833 | 6,784 | -1,321 | 2,322 | 7,785 | 53,350 | 846,468 |
| Effect of IFRS 15 and IFRS 16 | -21,509 | -21,509 | |||||||
| Tax effect of IFRS 15 and 16 | 6,979 | 6,979 | |||||||
| Adjusted balance at the beginning of the period | 528,303 | 831,938 | |||||||
| Net profit for the period | 0 | 0 | 55,981 | 0 | 0 | 0 | 0 | 0 | 55,981 |
| Other comprehensive income for the period | 0 | 0 | 0 | 1,416 | 6,856 | -1,672 | 6,600 | 0 | 6,600 |
| Total comprehensive income for the period | 0 | 55,981 | 1,416 | 6,856 | -1,672 | 6,600 | 0 | 62,581 | |
| Transactions with owners: | |||||||||
| Share-based payments | 0 | 0 | 5,850 | 0 | 0 | 0 | 0 | 0 | 5,850 |
| Deferred tax on share-based payments | 0 | 0 | -843 | 0 | 0 | 0 | 0 | 0 | -843 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -53,350 | -53,350 |
| Balance at the end of the period | 250,000 | -7,500 | 589,291 | 8,200 | 5,535 | 650 | 14,385 | 0 | 846,176 |
Notes Note 1 Accounting policies
The consolidated financial statements for the first three months of 2018 have been prepared in accordance with IAS 34 'Interim Financial Reporting' and on the basis of the same accounting policies as were applied in the Annual Report 2017, besides what is stated below.
The financial reporting including the consolidated financial statements for the first three months of 2018 and Management's review have been prepared in accordance with additional Danish disclosure requirements for interim report of listed companies. See pages 57 to 63 of the Annual Report 2017 for a comprehensive description of the accounting policies applied.
Changes in accounting policies
As of January 2018 NNIT A/S has implemented the following new [or amended and revised] accounting standards and interpretations (IFRSs):
- IFRS 9 "Financial instruments"
- IFRS 15 "Revenue from Contracts with Customers"
- IFRS 16 "Leasing" (early adoption)
It is only IFRS 15 and IFRS 16 which have affected the recognition and measurement of the consolidated financial statements for the first three months of 2018. Both standards have been applied fully retrospectively as of January 1, 2018, thus the 2017 comparative figures have been adjusted.
IFRS 15
IFRS 15 "Revenue from Contracts with Customers" introduces a new model for recognition of revenue.
Revenue in accordance with the new standard is recognized when an asset on behalf of a customer is created with no alternative use and NNIT has an enforceable right to payment for performance completed to date, or the customer obtains control of a service and thus has the ability to direct the use and obtain the benefit from the service.
The standard has impacted NNITs outsourcing contracts. Revenue and operating profit on some phases in outsourcing contracts has been postponed to later periods other than the period during which the activities are performed.
This postponement arises from the fact that some of the activities performed in the transition phases do not transfer services to the customer under IFRS 15. In this case, the costs incurred to perform those activities are considered start-up costs, which are capitalized and amortized over the operation period.
IFRS 16
All leases have been recognized in the balance sheet with a corresponding lease debt except for short-term assets and low value assets. Leased assets are depreciated over the lease term, and payments are allocated between installments on the lease obligation and interest expense, classified as financial expenses.
IFRS 9
In relation to hedge accounting, the standard provides more opportunities for applying proxy hedges and repeals the requirement for retrospective effectiveness testing.
17 of 22 NNIT A/S Østmarken 3A Telephone: +45 7024 4242 2860 Søborg www.nnit.com Denmark CVR No: 21 09 31 06
The implementation of IFRS 9 has not resulted in a different recognition for accounting purposes in relation to hedge accounting or other financial instruments.
The effect of IFRS 15 and IFRS 16 are shown in the table below.
| DKK '000 | December 31, 2017 | March 31, 2017 | |||||
|---|---|---|---|---|---|---|---|
| Previous | Effect of | Previous | Effect of | New | |||
| practice | change | New practice | practice | change | practice | ||
| Assets | |||||||
| Tangible assets | 573,982 | 366,715 | 940,697 | 444,169 | 412,148 | 856,317 | |
| Contract assets | 0 | 179,330 | 179,330 | 160,701 | 160,701 | ||
| Deferred tax | 52,548 | 12,469 | 65,017 | 44,818 | 7,192 | 52,010 | |
| Total non-current assets | 871,224 | 558,514 | 1,429,738 | 550,888 | 580,041 | 1,130,929 | |
| Work in progress | 122,868 | -66,799 | 56,069 | 149,288 | -39,585 | 109,703 | |
| Total current assets | 956,799 | -66,799 | 890,000 | 993,055 | -39,585 | 953,470 | |
| Total assets | 1,828,023 | 491,715 | 2,319,738 | 1,543,943 | 540,456 | 2,084,399 | |
| Equity and liabilities | |||||||
| Total equity | 1,005,314 | -31,323 | 973,991 | 860,512 | -14,336 | 846,176 | |
| Leasing liability | 0 | 295,950 | 295,950 | 345,823 | 345,823 | ||
| Provisions | 13,245 | 11,477 | 24,722 | 11,931 | 11,644 | 23,575 | |
| Total non-current liabilities | 82,987 | 307,427 | 390,414 | 31,006 | 357,467 | 388,473 | |
| Prepayments received | 158,428 | 135,225 | 293,653 | 168,951 | 122,140 | 291,091 | |
| Leasing liability | 0 | 80,920 | 80,920 | 75,531 | 75,531 | ||
| Other current liabilities | 132,617 | -534 | 132,083 | 103,321 | -346 | 102,975 | |
| Total current liabilities | 739,722 | 215,611 | 955,333 | 652,425 | 197,325 | 849,750 | |
| Total equity and liabilities | 1,828,023 | 491,715 | 2,319,738 | 1,543,943 | 540,456 | 2,084,399 | |
| Income statement | |||||||
| Revenue | 2,891,878 | -40,491 | 2,851,387 | 715,310 | -198 | 715,112 | |
| Cost of goods sold | 2,362,506 | -26,210 | 2,336,296 | 581,709 | -2,012 | 579,697 | |
| Gross profit | 529,372 | -14,281 | 515,091 | 133,601 | 1,814 | 135,415 | |
| Sales and marketing costs | 135,563 | -337 | 135,226 | 32,903 | -92 | 32,811 | |
| Administrative expenses | 116,986 | -685 | 116,301 | 27,870 | -221 | 27,649 | |
| Operating profit | 276,823 | -13,259 | 263,564 | 72,828 | 2,127 | 74,955 | |
| Financial income | 5,059 | 0 | 5,059 | 2,055 | 0 | 2,055 | |
| Financial expenses | 5,993 | 9,112 | 15,105 | 3,656 | 2,131 | 5,787 | |
| Profit before income taxes | 275,889 | -22,371 | 253,518 | 71,227 | - 4 |
71,223 | |
| Income taxes | 59,410 | -5,417 | 53,993 | 15,415 | -173 | 15,242 | |
| Net profit for the period | 216,479 | -16,954 | 199,525 | 55,812 | 169 | 55,981 | |
| Earnings per share | |||||||
| Earnings per share | 8.89 | -0.70 | 8.20 | 2.30 | 0.01 | 2.31 | |
| Diluted earnings per share | 8.68 | -0.68 | 8.00 | 2.29 | 0.01 | 2.30 | |
| Earnings per share, effect of IFRS 15 | -0.70 | 0.00 | |||||
| Diluted earnings per share, effect of IFRS 15 | -0.68 | 0.00 | |||||
| Earnings per share, effect of IFRS 16 | 0.00 | 0.01 | |||||
| Diluted earnings per share, effect of IFRS 16 | 0.00 | 0.01 | |||||
18 of 22 NNIT A/S Østmarken 3A Telephone: +45 7024 4242 2860 Søborg www.nnit.com Denmark CVR No: 21 09 31 06
Note 2 Quarterly numbers
| 2018 | 2017 | ||||||
|---|---|---|---|---|---|---|---|
| DKK '000 | Q1 | Q4 | Q3 | Q2 | Q1 | ||
| Revenue | 698,502 | 779,722 | 661,464 | 695,089 | 715,112 | ||
| Cost of goods sold | 579,145 | 612,807 | 571,039 | 572,753 | 579,697 | ||
| Gross profit | 119,357 | 166,915 | 90,425 | 122,336 | 135,415 | ||
| Sales and marketing costs | 31,975 | 35,870 | 33,786 | 32,758 | 32,812 | ||
| Administrative expenses | 26,681 | 31,549 | 28,602 | 28,501 | 27,649 | ||
| Operating profit | 60,701 | 99,496 | 28,037 | 61,077 | 74,954 | ||
| Net financials | -2,022 | -4,270 | 1,324 | -3,368 | -3,732 | ||
| Profit before income taxes | 58,679 | 95,226 | 29,361 | 57,709 | 71,222 | ||
| Income taxes | 12,869 | 21,602 | 6,166 | 10,984 | 15,242 | ||
| Net profit for the period | 45,810 | 73,624 | 23,195 | 46,725 | 55,980 |
Segment disclosures
| 2018 | 2017 | ||||
|---|---|---|---|---|---|
| DKK '000 | Q1 | Q4 | Q3 | Q2 | Q1 |
| Revenue by business area | |||||
| Operations | 425,611 | 480,475 | 438,310 | 440,405 | 472,703 |
| hereof Novo Nordisk Group | 169,884 | 220,909 | 192,634 | 180,207 | 224,993 |
| hereof non-Novo Nordisk Group | 255,727 | 259,566 | 245,676 | 260,198 | 247,710 |
| Solutions | 272,891 | 299,247 | 223,154 | 254,684 | 242,409 |
| hereof Novo Nordisk Group | 86,200 | 97,547 | 86,220 | 86,955 | 95,936 |
| hereof non-Novo Nordisk Group | 186,691 | 201,699 | 136,933 | 167,729 | 146,473 |
| Total revenue | 698,502 | 779,722 | 661,464 | 695,089 | 715,112 |
| Revenue by customer group | |||||
| Life Sciences | 355,321 | 413,866 | 372,063 | 364,527 | 409,548 |
| hereof Novo Nordisk Group | 256,084 | 318,457 | 278,854 | 267,162 | 320,928 |
| Enterprise | 187,251 | 191,300 | 177,458 | 164,497 | 151,034 |
| Public | 99,379 | 114,992 | 57,104 | 95,641 | 86,114 |
| Finance | 56,551 | 59,564 | 54,839 | 70,424 | 68,416 |
| Total revenue | 698,502 | 779,722 | 661,464 | 695,089 | 715,112 |
| Operating profit by business area | |||||
| Operations | 32,313 | 62,362 | 47,167 | 44,407 | 50,856 |
| Solutions | 28,388 | 37,134 | -19,130 | 16,670 | 24,098 |
| Total operating profit | 60,701 | 99,496 | 28,037 | 61,077 | 74,954 |
| Ammortization, depreciation and impairment losses | |||||
| Operations | 52,790 | 47,773 | 48,764 | 51,288 | 50,967 |
| Solutions | 8,999 | 9,285 | 8,859 | 7,771 | 7,180 |
| Total ammortization, depreciation and impairment losses | 61,789 | 57,058 | 57,623 | 59,059 | 58,148 |
The Danish operations generated 87.9% of NNIT's revenue in 3M 2018 and 90.0% in 3M 2017 based on the location of customer purchase orders. As a consequence of the predominantly Danish revenue, we will not disclose a geographical revenue split.
Note 3
Related party transactions
| DKK'000 | March 31, 2018 |
March 31, 2017 |
Dec 31, 2017 |
|---|---|---|---|
| Assets | |||
| Receivables from related parties | 143,430 | 126,633 | 216,151 |
| Work in progress related parties | 307,763 | 52,819 | 37,652 |
| Liabilities | |||
| Liabilities to related parties | 91,953 | 71,191 | 1,264 |
| Prepayments from related parties | 27,615 | 72,150 | 48,760 |
Note 4
Contingent liabilities and legal proceedings
Contingent liabilities
None
Legal proceedings
None
Note 5
Currency hedging
NNIT's objective is at any time to limit the company's financial risks.
NNIT is exposed to exchange rate risks in the countries where NNIT has its main activities. The majority of NNIT's sales are in DKK and EUR, implying limited foreign exchange risk, due to the parent company's functional currency being DKK and Denmark's fixed-rate policy towards EUR. NNIT's foreign exchange risk therefore primarily stems from transactions carried out in the currencies of other countries in which NNIT mainly operates: primarily the Chinese yuan, and, to a lesser extent, the Czech koruna, the Philippine peso, the Swiss franc and the British pound.
At present NNIT's sales in Chinese yuan, Czech koruna, and Swiss franc are not sufficiently to balance these currency risks. To manage foreign exchange rate risks, NNIT has entered into hedging contracts to hedge major foreign currency balances in Chinese yuan, Czech koruna and the Philippine peso. Due to the size of the exposure Swiss franc is not hedged.
Cumulative profit on derivative financial instruments regarding future cash flow per March 31, 2018 is recognized in Equity (Other comprehensive income) with an amount of DKK 4.2m before tax (DKK 3.3m after tax).
Note 6
Currency sensitivity and development
Currency sensitivities
| Estimated annual impact on NNIT's operating profit of a 10% increase in the outlined currencies against DKK* |
Hedging period (months) |
|
|---|---|---|
| EUR | DKK 35 million | - |
| CNY | DKK -19 million | 14 |
| CZK | DKK -10 million | 14 |
| PHP | DKK -5 million | 14 |
| USD | DKK -4 million | - |
| CHF | DKK -1 million | - |
Hedging gains and losses do not impact operating profit as they are recognized under net financials. For further details on hedging, please see note 6 above.
* The above sensitivities address hypothetical situations and are provided for illustrative purposes only. The sensitivities assume the business develops consistent with the current 2018 business plan.
Key currency assumptions
| DKK per 100 | 2016 average exchange rates |
2017 average exchange rates |
YTD 2018 average exchange rates at May 9, 2018 |
Current exchange rates at May 9, 2018 |
|---|---|---|---|---|
| CNY | 101.29 | 97.57 | 95.68 | 98.50 |
| EUR | 744.52 | 743.86 | 744.71 | 744.95 |
| CZK | 27.54 | 28.27 | 29.32 | 29.14 |
| PHP | 14.17 | 13.08 | 11.76 | 12.07 |
| CHF USD |
683.13 673.27 |
669.63 659.53 |
635.40 607.21 |
626.27 627.12 |
Currency development
NNIT has a net cost exposure in the Chinese yuan, the Czech koruna (CZK), the Philippine peso and the Swiss franc and therefore the depreciation of the Philippine peso versus Danish kroner had a positive impact on reported operating profit, whereas the increase in the Czech koruna had the reverse effect.
2860 Søborg www.nnit.com Denmark CVR No: 21 09 31 06
NNIT has hedged 90% of its net exposure in Chinese yuan (CNY hedged with CNH (CNY offshore)) and Czech koruna (CZK) for the coming 14 months.
Note 7
Performance in constant and reported currencies Performance overview
| DKK million (reported currencies) |
Q1 2018 | Q1 2018 (constant*) |
Q1 2017 | Change | Change (constant) |
|---|---|---|---|---|---|
| Revenue | 698.5 | 706.7 | 715.1 | -2.3% | -1.2% |
| Cost of goods sold | 579.1 | 588.6 | 579.7 | -0.1% | 1.5% |
| Gross profit | 119.4 | 118.1 | 135.4 | -11.9% | -12.8% |
| Gross profit margin | 17.1% | 16.7% | 18.9% | -1.8pp | -2.2pp |
| Sales and marketing costs | 32.0 | 32.3 | 32.8 | -2.6% | -1.6% |
| Administrative expenses | 26.7 | 26.9 | 27.6 | -3.5% | -2.7% |
| Operating profit | 60.7 | 58.9 | 75.0 | -19.0% | -21.4% |
| Operating profit margin | 8.7% | 8.3% | 10.5% | -1.8pp | -2.1pp |
| Net financials | -2.0 | n.a. | -3.7 | -45.8% | n.a. |
| Profit before tax | 58.7 | n.a. | 71.2 | -17.6% | n.a. |
| Tax | 12.9 | n.a. | 15.2 | -15.6% | n.a. |
| Effective tax rate | 21.9% | n.a. | 21.4% | 0.5pp | n.a. |
| Net profit | 45.8 | n.a. | 56.0 | -18.2% | n.a. |
*Constant currencies measured using average exchange rates for Q1 2017.
Revenue distribution
| DKKm (reported currencies) |
Q1 2018 | Q1 2018 (constant*) |
Q1 2017 | Pct Change (reported) |
Pct Change (constant) |
|---|---|---|---|---|---|
| Novo Nordisk Group | 256.1 | 259.9 | 320.9 | -20.2% | -19.0% |
| Other Life Sciences | 99.2 | 103.4 | 88.6 | 12.0% | 16.7% |
| Enterprise | 187.3 | 187.4 | 151.0 | 24.0% | 24.1% |
| Public | 99.4 | 99.4 | 86.1 | 15.4% | 15.4% |
| Finance | 56.6 | 56.6 | 68.4 | -17.3% | -17.3% |
| Total | 698.5 | 706.7 | 715.1 | -2.3% | -1.2% |
*Constant currencies measured using average exchange rates for Q1 2017.